SWOG clinical trial number
SWOG-9310 (INT-0143) (RTOG-93-10)

An Intergroup Phase II Combined Modality Treatment of Primary Central Nervous System Lymphoma

Closed
Phase
Published
Abbreviated Title
Combined Modality Treatment of CNS Lymphoma
Activated
12/15/1994
Closed
12/01/1997
Participants
NCORP, Members

Research committees

Brain Cancer
Lymphoma

Other Clinical Trials

S2308
SWOG Clinical Trial Number

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

Research Committee(s)
Lymphoma
Activated
08/01/2024
14% Accrual
Accrual
14%
Open
Phase
S2207
SWOG Clinical Trial Number

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma

Research Committee(s)
Lymphoma
Activated
06/30/2023
12% Accrual
Accrual
12%
Open
Phase
CTSU/AHOD2131
SWOG Clinical Trial Number

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase